Cancer “vaccines” enter the neoantigen stage
Attempts to raise a personalised immune response against neoantigens have attracted big pharma interest, most recently from Merck & Co.
Ultragenyx sees enough in Angelman
The group buys out its partner Genetx, but inconsistent data spook investors.
Alnylam shoots for the heart
With readout of Apollo-B approaching, can Onpattro succeed where Bridgebio’s acoramidis failed?
AACR 2022 – Biontech’s cell therapy effort bears fruit at last
But it’s still far too early to tell whether combining Car-T with an mRNA vaccine might improve response durability.
